Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis.
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Drugs, Chinese Herbal
/ therapeutic use
Female
Humans
Injections
/ methods
Male
Medicine, Chinese Traditional
/ methods
Middle Aged
Neoplasms
/ drug therapy
Phytotherapy
/ methods
Propensity Score
Quality of Life
Retrospective Studies
Aidi injection
ECOG score
chemotherapy-related toxicity
performance status
propensity score match
quality of life
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
pubmed:
30
11
2018
medline:
18
12
2019
entrez:
29
11
2018
Statut:
ppublish
Résumé
Clinical research has paid increasing attention to quality of life (QoL) in recent years, but the assessment of QoL is difficult, hampered by the subjectivity, complexity, and adherence of patients and physicians. According to previous studies, QoL in cancer patients is related to performance status (PS) and influenced by chemotherapy-related toxicity. Aidi injection, a traditional Chinese medicine injection, is used as an adjuvant drug to enhance effectiveness of chemotherapy. The study aims to investigate whether Aidi injection could improve QoL by improving PS and reducing toxicity caused by chemotherapy. A retrospective cohort study was performed at the First Affiliated Hospital of Anhui Medicine University. Data of consecutive patients diagnosed with cancers between January 2014 and June 2017 were retrieved from the electronic medical record system. After a 1:1 propensity score match, patients were then divided into 2 groups based on the therapies used, that is, Aidi injection combined with chemotherapy and chemotherapy alone, and the PS, chemotherapy-related toxicity, and combined medication information were compared. The effect of different dosages of Aidi injection on patients was further explored. A total of 3200 patients were included in this study. Aidi injection combined with chemotherapy exhibited significantly benefit in PS ( P < .001, odds ratio [OR] 3.4, 95% confidence interval [CI] 2.4-4.8) compared with chemotherapy alone after adjusting for the factors that affect PS. The improvement rate of PS in the Aidi group was significantly higher than in the control group across the stratification of gender, age, tumor type, TNM stage, body mass index, nodal metastasis, prior chemotherapy, chemotherapy regimens, other Chinese tradition medicines, and chemotherapy cycle. Meanwhile, Aidi injection used synchronously with chemotherapeutic drugs could decrease the incident rate of damage to liver and kidney function, myelosuppression, and gastrointestinal reactions caused by chemotherapy. It was indicated that the integrative approach combining chemotherapy with Aidi injection, especially with the conventional dosage of Aidi injection, had significant benefit on QoL in cancer patients.
Sections du résumé
BACKGROUND
Clinical research has paid increasing attention to quality of life (QoL) in recent years, but the assessment of QoL is difficult, hampered by the subjectivity, complexity, and adherence of patients and physicians. According to previous studies, QoL in cancer patients is related to performance status (PS) and influenced by chemotherapy-related toxicity. Aidi injection, a traditional Chinese medicine injection, is used as an adjuvant drug to enhance effectiveness of chemotherapy. The study aims to investigate whether Aidi injection could improve QoL by improving PS and reducing toxicity caused by chemotherapy.
METHODS
A retrospective cohort study was performed at the First Affiliated Hospital of Anhui Medicine University. Data of consecutive patients diagnosed with cancers between January 2014 and June 2017 were retrieved from the electronic medical record system. After a 1:1 propensity score match, patients were then divided into 2 groups based on the therapies used, that is, Aidi injection combined with chemotherapy and chemotherapy alone, and the PS, chemotherapy-related toxicity, and combined medication information were compared. The effect of different dosages of Aidi injection on patients was further explored.
RESULTS
A total of 3200 patients were included in this study. Aidi injection combined with chemotherapy exhibited significantly benefit in PS ( P < .001, odds ratio [OR] 3.4, 95% confidence interval [CI] 2.4-4.8) compared with chemotherapy alone after adjusting for the factors that affect PS. The improvement rate of PS in the Aidi group was significantly higher than in the control group across the stratification of gender, age, tumor type, TNM stage, body mass index, nodal metastasis, prior chemotherapy, chemotherapy regimens, other Chinese tradition medicines, and chemotherapy cycle. Meanwhile, Aidi injection used synchronously with chemotherapeutic drugs could decrease the incident rate of damage to liver and kidney function, myelosuppression, and gastrointestinal reactions caused by chemotherapy.
CONCLUSION
It was indicated that the integrative approach combining chemotherapy with Aidi injection, especially with the conventional dosage of Aidi injection, had significant benefit on QoL in cancer patients.
Identifiants
pubmed: 30482065
doi: 10.1177/1534735418810799
pmc: PMC6432675
doi:
Substances chimiques
Antineoplastic Agents
0
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735418810799Références
Health Qual Life Outcomes. 2003 Nov 24;1:71
pubmed: 14636426
PLoS One. 2017 Jun 7;12(6):e0178676
pubmed: 28591157
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S370-8
pubmed: 24590434
Cancer Med. 2015 Jun;4(6):800-7
pubmed: 25641947
Asian Pac J Cancer Prev. 2015;16(11):4781-6
pubmed: 26107240
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
J Cancer Res Ther. 2016 Oct;12(Supplement):11-14
pubmed: 27721243
Dig Liver Dis. 2016 Apr;48(4):429-34
pubmed: 26776878
Chin J Integr Med. 2019 Oct;25(10):785-790
pubmed: 29335858
Ann Surg. 2015 Dec;262(6):e110
pubmed: 24836146
Pharmazie. 2011 Feb;66(2):83-97
pubmed: 21434569
Cancer Treat Rev. 2016 Nov;50:194-199
pubmed: 27718458
Asian Pac J Cancer Prev. 2014;15(23):10413-20
pubmed: 25556485
Pharm Res. 2008 Sep;25(9):2097-116
pubmed: 18626751
J Integr Med. 2014 Jul;12(4):331-5
pubmed: 25074882
Stat Med. 2012 Mar 30;31(7):653-60
pubmed: 22161304
J Oncol Pract. 2015 Mar;11(2):e216-21
pubmed: 25563703
JAMA. 2018 May 1;319(17):1802-1813
pubmed: 29715359
Surgery. 2003 May;133(5):507-11
pubmed: 12773978
Mol Med Rep. 2012 Jun;5(6):1415-8
pubmed: 22427100
J Tradit Chin Med. 2013 Jun;33(3):413-6
pubmed: 24024343
Am J Clin Oncol. 1988 Dec;11(6):630-3
pubmed: 3055933
Evid Based Complement Alternat Med. 2018 Jun 11;2018:7918258
pubmed: 29991956
Mol Med Rep. 2018 Jul;18(1):131-138
pubmed: 29749455
J Clin Oncol. 2016 Aug 10;34(23):2769-75
pubmed: 27354484
J Tradit Chin Med. 2011 Mar;31(1):10-6
pubmed: 21563499
Cell Physiol Biochem. 2017;43(5):1829-1840
pubmed: 29050003
Medicine (Baltimore). 2017 May;96(21):e7005
pubmed: 28538415
J Ginseng Res. 2018 Jul;42(3):248-254
pubmed: 29983605
Curr Opin Support Palliat Care. 2018 Jun;12(2):174-180
pubmed: 29697417
Hepatogastroenterology. 2002 Jul-Aug;49(46):1062-5
pubmed: 12143202
Medicine (Baltimore). 2016 Nov;95(44):e5210
pubmed: 27858864
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 May;29(5):394-7
pubmed: 19673326
Support Care Cancer. 2015 Dec;23(12):3645-52
pubmed: 26314706
Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):99-106
pubmed: 16487042
J Tradit Chin Med. 2015 Aug;35(4):361-74
pubmed: 26427104
Med Oncol. 2018 Aug 20;35(10):132
pubmed: 30128793
J Cancer Res Ther. 2014 Aug;10 Suppl 1:52-5
pubmed: 25207892
ESMO Open. 2017 Nov 23;2(5):e000261
pubmed: 29215098
Curr Drug Targets. 2016;17(12):1331-40
pubmed: 26343107
Biomed Res Int. 2018 Apr 23;2018:1245616
pubmed: 29850483
Zhongguo Zhong Yao Za Zhi. 2015 Sep;40(18):3674-81
pubmed: 26983220
Rheum Dis Clin North Am. 2018 May;44(2):203-213
pubmed: 29622292
Chin J Integr Med. 2017 Jul;23(7):504-509
pubmed: 27484766